Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity...
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
About this item
Full title
Author / Creator
Aroor, Annayya R. , Das, Nitin A. , Carpenter, Andrea J. , Habibi, Javad , Jia, Guanghong , Ramirez-Perez, Francisco I. , Martinez-Lemus, Luis , Manrique-Acevedo, Camila M. , Hayden, Melvin R. , Duta, Cornel , Nistala, Ravi , Mayoux, Eric , Padilla, Jaume , Chandrasekar, Bysani and DeMarco, Vincent G.
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown promise in reducing arterial stiffness and the risk of cardiovascular an...
Alternative Titles
Full title
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_762775bbe4d347228d8b8580356663b2
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_762775bbe4d347228d8b8580356663b2
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-018-0750-8
